Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

J&J unit exits insulin pump business

Johnson & Johnson’s diabetes care unit will shut down its business in the United States and Canada amid increased competition and after failing to find a buyer.

Read More »

Acadia Scraps Phase II Alzheimer’s Trial, Gets Breakthrough Tag for Dementia-Related Drug

After posting mixed results for its pimavanserin trial in December 2016, Acadia Pharmaceuticals is broadening its research focus from Alzheimer’s disease psychosis to the treatment of hallucinations and delusions associated with dementia-related psychosis.

Read More »

FDA approves Mylan’s Copaxone copy

Mylan received long-awaited U.S. approval for its generic version of rival Teva’s blockbuster multiple sclerosis treatment Copaxone.

Read More »

Sarepta Jumps Despite DMD Safety Issues in FDA Database

Shares of Sarepta Therapeutics recovered from a dip of about 8 percent as investors seem to have rallied behind the company’s Duchenne muscular dystrophy (DMD) drug Exondys 51.

Read More »

Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder.

Read More »

Ex-Biotech Analyst Charged With Insider Trading

The U.S. Attorney’s Office in Chicago charged a former Zacks biotech analyst with securities fraud over allegations of insider trading.

Read More »

FDA pours cold water on PTC Therapeutics’ Duchenne drug application

PTC Therapeutics Inc. failed to supply persuasive evidence that its experimental drug to treat a form of Duchenne muscular dystrophy is effective, the U.S. Food and Drug Administration said, dealing a blow to the company’s years-long effort to bring the drug to market.

Read More »

PureTech’s Gelesis says obesity drug achieved weight loss in study

PureTech subsidiary Gelesis is moving closer to filing for regulatory approval of its obesity treatment Gelesis100 after results of the latest study, the company said.

Read More »

Deaths, Serious Liver Injury Linked to Ocaliva

The FDA warned health-care providers to stick to dosing recommendations for Intercept Pharma’s liver disease medicine Ocaliva after 19 patient deaths were reported.

Read More »

Nabriva’s pneumonia drug succeeds in late-stage trial

Nabriva Therapeutics’ experimental antibiotic lefamulin for CABP met the main goal of a late-stage study.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom